Akari Therapeutics to Present Data from Phase 2 PNH Trial of Coversin at the 22nd Congress of the European Hematology Association

NEW YORK and LONDON, June 23, 2017 — Akari Therapeutics (NASDAQ: AKTX), a clinical-stage biopharmaceutical company, is presenting a poster today at the 22nd Congress of the European Hematology Association (EHA) in Madrid, Spain containing data for the four patients, to date, who have completed its ongoing Phase 2 trial of Coversin in paroxysmal nocturnal […]

Akari Therapeutics Announces Resignation of CEO

- Executive Chairman to Continue to Fulfill Interim CEO Duties as Board Commences Executive Search – Data Correction for Fifth Patient in Phase 2 PNH Trial for Coversin May 30, 2017 06:02 PM Eastern Daylight Time NEW YORK & LONDON–(BUSINESS WIRE)–Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, today announced the resignation of Gur […]

Akari Therapeutics Announces Edison’s Withdrawal of Edison Report titled “Akari’s Coversin matches Soliris in Phase II”

NEW YORK and LONDON, April 27, 2017 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, released today a statement that Edison Investment Research Ltd. has withdrawn its report issued yesterday titled “Akari’s Coversin matches Soliris in Phase II” (the “Edison Report”) because it contains material inaccuracies, including without limitation, with respect to Akari’s […]

Akari Therapeutics Demonstrates Positive Response with Coversin in Ongoing Phase 2 PNH Trial and In Additional Clinical Targets

NEW YORK and LONDON, April 24, 2017 -Interim Phase 2 PNH data demonstrate positive response with Coversin™ -Phase 3 PNH program expected to commence in 4Q2017 -Data from preclinical aHUS model demonstrates positive results -New preclinical data demonstrates positive response of Coversin’s combined C5 and LTB4 therapy in skin and eye models -Phase 2 programs […]

Akari Therapeutics to Present at the Jefferies Complement Symposium

NEW YORK and LONDON, April 3, 2017 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that Dr. Gur Roshwalb, Chief Executive Officer, will present at the Jefferies Complement Symposium on April 6, 2017, in Boston, Massachusetts. The company is scheduled to present at 2:10 PM ET. Click here to see full […]